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lostridium  difﬁcile  infection  is a  frequent  but
ell-controlled event  after  hematopoietic  cell
ransplantation
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lostridium difﬁcile infection (CDI) is the most common cause
f nosocomial diarrhea and represents a frequent and impor-
ant source of gastrointestinal morbidity after hematopoietic
tem cell transplantation (HSCT). Patients undergoing HSCT
ave several risk factors for the development of CDI, including
ultiple prior hospitalizations, frequent use of wide spectrum
ntibiotics, disease- and treatment-related immunosuppres-
ion and mucosal barrier disruption secondary to conditioning
egimens, particularly when they are myeloablative or include
otal body irradiation. Consequently, patients undergoing
SCT have an incidence of CDI that is higher than the general
ospitalized population; it is as high as 15–30% after allogeneic
SCT.1
The majority of reports of CDI in HSCT patients originate
rom transplant centers located in developed countries. The
anuscript by Pilcante et al.2 is the ﬁrst report of the inci-
ence, risk factors and outcomes of CDI in patients undergoing
SCT in an academic medical center in Chile.
The results presented are compatible with other reports,
onﬁrming the global importance of CDI in HSCT patients.
hen compared to previous reports, the incidence of CDI
bserved in this study appears to be in the lower portion
f the reported spectrum, possibly as a result of multiple
actors, including antibiotic use patterns, cultural dietary
abits, and possibly the degree of C. difﬁcile colonization
ffecting the general hospitalized patient population of Chile.
ecent reports by Kinnebrew3 and Bruminhent4 show high
ates of colonization by C. difﬁcile at the time of admission
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eserved.for the HSCT procedure in two US centers. Development of
CDI was preceded by colonization, with rare cases of CDI
developing in patients without previous colonization. It is
possible that lower colonization rates at admission were the
main determinant for a lower incidence of CDI in Chilean
patients undergoing HSCT. As in other publications, the
majority of CDI cases occurred early in the transplant period,
with 40% of cases occurring within the ﬁrst seven days. How-
ever, the median time to CDI was longer than other studies,
suggesting that late infections had a larger effect in this
cohort. Again, prior hospitalizations, antibiotic use patterns
and the rate of colonization may have had an impact on these
results.
While previous studies have observed an association of CDI
with the development of acute GVHD (aGVHD), and increased
risk of gastrointestinal aGVHD,5 this ﬁnding has not been con-
sistent. It has been postulated that CDI may represent the
initial insult that stimulates the immune response against
the gastrointestinal tract. However, the higher rate of aGVHD
could have occurred due to increased testing in patients with
CDI as part of the clinical evaluation of diarrhea in the post-
transplant setting. Moreover, patients with aGVHD require
frequent hospitalizations and have increased risk of infectious
complications and antibiotic use. In a recent study, Guddati
et al. reported that patients with GVHD had a higher rate of Cleveland, OH, United States.
C. difﬁcile colonization in post-engraftment hospitalizations,
likely as a result of the increased need for medical interven-
tions and inpatient care.
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hematopoietic stem cell transplant recipients: a prospective
study of the epidemiology and outcomes involving toxigenic
and  nontoxigenic strains. Biol Blood Marrow Transplant. 2015,
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The association observed between CDI and longer time to
neutrophil engraftment in allogeneic HSCT observed in the
study by Pilcante et al. needs to be interpreted with caution.2
One previous study identiﬁed the use of umbilical cord blood
grafts as a risk factor for CDI, likely as a result of their slower
engraftment.7 However, the presence of a correlation between
CDI and delayed engraftment is not sufﬁcient to establish a
causal relationship. The reverse causation could be possible
(delayed engraftment causing increase in CDI) or both CDI and
slower engraftment could be the result of other risk factors (i.e.
intensity of conditioning chemotherapy, myelosuppressive
antibiotics, prior bone marrow damage or immunosuppres-
sion, etc.). Subsequent studies should focus on the speciﬁc
sequence of events and the presence or other clinical and
laboratory risk factors for delayed engraftment.
Diarrheal illness is a common event in the post HSCT
period, and CDI should be considered high in the differen-
tial diagnosis. While earlier literature suggested that CDI in
HSCT recipients was more  severe and was associated with
increased non-relapse mortality,8 recent retrospective anal-
yses suggest that the majority of cases of CDI are mild to
moderate and respond well to antibiotic therapy.5,9 The out-
comes reported by Pilcante et al. conﬁrm that most patients
experience mild diarrheal illness that responds to a single
course of antibiotics.2 Moreover, transplant outcomes and
overall survival do not appear to be affected by the incidence of
CDI. These and other results suggest that while CDI is common
after HSCT, it is rarely a life-threatening event. Over the last
decade, heightened awareness, improved testing methods and
early treatment of CDI in HSCT recipients have contributed to
a reduction in the severity of the diarrheal illness associated
ereby limiting its impact on post-transplant outcomes.
Conﬂicts  of  interest
The author declares no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s. Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difﬁcile
infection in the hematopoietic unit: a meta-analysis of 2 0 1 5;3  7(6):371–372
published studies. Biol Blood Marrow Transplant.
2014;20(10):1650–4.
. Pilcante JE, Rojas P, Ajenjo M, Sarmiento M, Ocqueteau M,  Ernst
D, et al. Clostridium difﬁcile infection in patients undergoing
hematopoietic cell transplantation. Results from the
transplantation group at the Hospital Clínico Pontiﬁcia
Universidad Católica, Santiago, Chile. Rev Bras Hematol
Hemoter. 2015;37(6):388–94.
. Kinnebrew MA, Lee YJ, Jenq RR, Lipuma L, Littmann ER,
Gobourne A, et al. Early Clostridium difﬁcile infection during
allogeneic hematopoietic stem cell transplantation. PLOS ONE.
2014;9(3):e90158.
. Bruminhent J, Wang ZX, Hu C, Wagner J, Sunday R, Bobik B,
et al. Clostridium difﬁcile colonization and disease in patients
undergoing hematopoietic stem cell transplantation. Biol
Blood Marrow Transplant. 2014;20(9):1329–34.
. Alonso CD, Dufresne SF, Hanna DB, Labbé AC, Treadway SB,
Neofytos D, et al. Clostridium difﬁcile infection after adult
autologous stem cell transplantation: a multicenter study of
epidemiology and risk factors. Biol Blood Marrow Transplant.
2013;19(10):1502–8.
. Guddati AK, Kumar G, Ahmed S, Ali M, Kumar N, Hari P, et al.
Incidence and outcomes of Clostridium difﬁcile-associated
disease in hematopoietic cell transplant recipients. Int J
Hematol. 2014;99(6):758–65.
. Willems L, Porcher R, Lafaurie M, Casin I, Robin M,  Xhaard A,
et al. Clostridium difﬁcile infection after allogeneic
hematopoietic stem cell transplantation: incidence, risk
factors, and outcome. Biol Blood Marrow Transplant.
2012;18(8):1295–301.
. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difﬁcile
infection in allogeneic stem cell transplant recipients is
associated with severe graft-versus-host disease and
non-relapse mortality. Bone Marrow Transplant.
2000;26(8):871–6.
. Jain T, Croswell C, Urday-Cornejo V, Awali R, Cutright J,
Salimnia H, et al. Clostridium difﬁcile colonization in
